Review anchor
Endothelin receptor, ET-A/ET-B
PROTEIN FAMILY · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Endothelin receptor, ET-A/ET-B
CHEMBL2096678
PROTEIN FAMILY
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Endothelin receptor, ET-A/ET-B as ChEMBL target CHEMBL2096678, mapped to UniProt P24530. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL2096678
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P24530
Endothelin receptor type B
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Endothelin receptor, ET-A/ET-B matters
Endothelin receptor, ET-A/ET-B is reviewed as Endothelin receptor type B (UniProt P24530); Endothelin receptor, ET-A/ET-B shows approved-linked disease relevance led by hypertension. 5 more disease programs remain visible in the same review block.; 5 linked drugs keep this evidence frame grounded.; the current evidence base includes 0 approved drugs, 261 compounds, and 29 assays, with lead potency reaching pChEMBL 8.4.
Protein context
Endothelin receptor type B
Endothelin receptor type B Sequence length is 442 aa.
Review this target as Endothelin receptor, ET-A/ET-B, mapped to UniProt P24530. ChEMBL maps the protein component as Endothelin receptor type B. Sequence length is 442 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P24530
Protein
Disease context
hypertension
Endothelin receptor, ET-A/ET-B shows approved-linked disease relevance led by hypertension. 5 more disease programs remain visible in the same review block. 5 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include AMBRISENTAN, APROCITENTAN, BOSENTAN.
Start review with hypertension because it currently carries approved-linked support. Linked drugs include AMBRISENTAN, APROCITENTAN, BOSENTAN, MACITENTAN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
5 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 0 approved drugs, 261 compounds, and 29 assays for this target. The dominant activity type is KD. CHEMBL2373292 is the current potency anchor at pChEMBL 8.4.
Use CHEMBL2373292 as the tractability anchor when discussing potency (pChEMBL 8.4).
Activity source · ChEMBL 36 via Core Engine
pChEMBL 8.4
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Endothelin receptor, ET-A/ET-B matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P24530, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why hypertension is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
261
Total Compounds
29
Total Assays
0
Approved Drugs
IC50: 1.0, KI: 2.0, KD: 6.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL2373292
|
8.4 | Kd | — |
|
|
No preferred name
CHEMBL287169
|
7.5 | Kd | — |
|
|
No preferred name
CHEMBL27732
|
7.3 | Kd | — |
|
|
No preferred name
CHEMBL285368
|
7.0 | Kd | — |
|
|
No preferred name
CHEMBL28920
|
6.9 | Kd | — |
Source Header